| DICOM PS3.16 2016e - Content Mapping Resource |
|---|
Since this context group defines the sites, rather than routes of administration, if the exogenous substance is administered into a tumor, the code for the morphologic abnormality (M-8FFFF, SRT, "Tumor") is used, rather than the specific concept for the route (R-F2CD4, SRT, "Intratumor route") (which may also be present as the value for the separately encoded route of administration, if present).
| DICOM PS3.16 2016e - Content Mapping Resource |
|---|